Navigation Links
Study examines risk of severe blood sugar swings among diabetics taking fluoroquinolones
Date:8/14/2013

[EMARGOED UNTIL THURSDAY, AUG. 15] Diabetic patients taking oral fluoroquinolones, a frequently prescribed class of antibiotics, were found to have a higher risk of severe blood sugar-related problems than diabetic patients taking other kinds of antibiotics, according to a recent study from Taiwan published in Clinical Infectious Diseases. The increased risk was lowhyperglycemia (high blood sugar) or hypoglycemia (low blood sugar) related to the drugs occurred in fewer than one in 100 patients studiedbut clinicians should consider the higher risk when treating diabetic patients with fluoroquinolones, especially moxifloxacin, and prescribe them cautiously, the study's authors concluded.

Increased use of these drugs, commonly used to treat such illnesses as urinary tract infections and community-acquired pneumonia, has raised concerns about rare but severe adverse effects, including tendon rupture and heart arrhythmia. Previous studies have also indicated a relationship between fluoroquinolones and severe glucose-related abnormalities, known as dysglycemia, which includes hyperglycemia or hypoglycemia. Severe blood sugar swings can lead to serious health problems, including irreversible brain damage or even death. In 2006, one drug from the fluoroquinolone class, gatifloxacin, was withdrawn from the U.S. market due to the risk of blood sugar abnormalities.

To assess the risk of blood sugar swings in diabetic patients using specific fluoroquinolones, a team of researchers, led by Mei-Shu Lai, MD, PhD, at National Taiwan University in Taipei, conducted a population-based cohort study of approximately 78,000 people with diabetes in Taiwan from January 2006 to November 2007.

Using the claims database for Taiwan's national insurance program, the researchers analyzed data for diabetic outpatients who had received a new prescription for an antibiotic from one of three different classes of antibiotics: fluoroquinolones (levofloxacin, ciprofloxacin, or moxifloxacin); second-generation cephalosporins (cefuroxime, cefaclor, or cefprozil); or macrolides (clarithromycin or azithromycin). The study's authors then looked for any emergency department visits or hospitalizations for dysglycemia among these patients within 30 days of the start of their antibiotic therapy.

Diabetics using oral fluoroquinolones faced greater risk of severe blood sugar swings than diabetic patients using antibiotics in other classes, the researchers found. The risks varied according to the specific fluoroquinolone the patients were using: The absolute risk, or incidence, of hyperglycemia per 1,000 people studied was 6.9 for moxifloxacin, 3.9 for levofloxacin, and 4.0 for ciprofloxacin. The absolute risk of hypoglycemia was 10.0 for moxifloxacin, 9.3 for levofloxacin, and 7.9 for ciprofloxacin.

(By comparison, among diabetic patients taking antibiotics in the macrolides class, the absolute risk of hyperglycemia was lower, at 1.6 per 1,000, and 2.1 per 1,000 among those taking antibiotics in the cephalosporin class; for hypoglycemia, the absolute risk per 1,000 was 3.7 for macrolides and 3.2 for cephalosporins, respectively.)

"Our results identified moxifloxacin as the drug associated with the highest risk of hypoglycemia, followed by levofloxacin and ciprofloxacin," the study's authors wrote. "Other antibiotics should be considered if dysglycemia is a concern, such as a beta lactam or macrolide," noted Dr. Lai.


'/>"/>

Contact: Jerica Pitts
jpitts@pcipr.com
312-558-1770
Infectious Diseases Society of America
Source:Eurekalert

Related medicine news :

1. International Probiotics Association Objects to Media Depiction of AAD/CDD Study, Provides Further Insight to Study Results
2. UCLA Dentistry receives $5 million to study extracellular RNA in saliva
3. Pilot study finds ER patients drinking high-octane beer
4. Pradaxa Lawsuit Lawyers at Wright & Schulte LLC Disturbed by New Study Finding that Pradaxa Users Face Significantly Higher Risk of Bleeding Side-Effects
5. Study challenges popular perception of new hookup culture on college campuses
6. Study examines how truck drivers react to marketplace demands for speed and flexibility
7. Study finds that some depressed adolescents are at higher risk for developing anxiety
8. Onsite colposcopy clinic improves cancer screening rates: Study
9. Study: Many evangelicals are ambivalent about homosexuality and civil unions for gays
10. Study to investigate mental health care for prisoners
11. Study paints complex health portrait of single-room occupancy hotel tenants in Downtown Eastside
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and ... the ultimate weight loss and wellness program, at their world headquarters of Omni La ... immediate and long-term results to anyone seeking weight loss, personal development, a healthy lifestyle, ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... continuity to its innovative Unified Instance Manager architecture, meeting the needs of ... new version optimizes the unattended auto-dialing system without agents, Presence Robodialer, provides ...
(Date:12/8/2016)... ... 08, 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 ... the highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) ... Dr. Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) ...
(Date:12/8/2016)... ... December 08, 2016 , ... California Senate Bill (SB) 863, signed into law ... in 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition ... to the study, medical payments per claim in California decreased 4 percent in 2013 ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Care Act. Dr. Botelho advocates for the mass media launching of story movements ... ongoing opportunities to share their unfortunate experiences; such a movement can generate the ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Henry Schein, Inc. (Nasdaq: ... care products and services to office-based dental, animal health and ... equity investment in Marrodent, one of Poland,s ... $32 million. This transaction was announced on August 30, 2016. ... Poland since 2014, and Marrodent marks ...
(Date:12/8/2016)... 2016 Research and Markets has announced the addition ... to their offering. ... The report provides separate comprehensive analytics for ... and Rest of World. Annual estimates and forecasts are ... is provided for these markets. Market data and analytics are derived from ...
(Date:12/7/2016)... -- "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by ... drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... patent on Lantus expired in 2014. Lantus is the brand name ...
Breaking Medicine Technology: